Release Date: July 2016
Number of Pages: 213
Number of Tables and Figures: 44
Synopsis: Retinal disorders such as AMD (Age-Related Macular Degeneration) and diabetic eye disease can significantly impair vision by damaging the tissue layer at the back of the eye responsible for light detection. In severe cases, certain retinal disorders can even result in permanent blindness, making timely treatment critical.
Retinal disorders are typically treated with drugs, laser treatment or surgery. Largely dominated by anti-VEGF therapies, drugs remain the preferred approach to treat most cases of retinal disorders. Retinal disorder drug sales are expected to account for nearly $13 Billion by the end of 2016. The market is ripe for future growth with a number of product candidates in development, including long-acting anti-VEGF treatments, anti-PDGF agents, combination therapies, complement factor inhibitors and cell therapies.
The “Retinal Disorder Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the retinal disorder drugs ecosystem including application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for retinal disorder drugs from 2016 through to 2030. The forecasts are segmented for 3 therapeutic categories, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
Company Wide License (Global Site): USD 6,500
For a sample of the report or any further inquiries please contact email@example.com
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
The report has the following key findings:
The report covers the following topics:
Market forecasts are provided for each of the following submarkets and their subcategories:
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
Bausch & Lomb
BMS (Bristol-Myers Squibb)
CDI (Cellular Dynamics International)
Cell Cure Neurosciences
Chengdu Kanghong Biotech
Chengdu Kanghong Pharmaceuticals
Colby Pharmaceutical Company
Innovations in Sight
Roche Holding (F. Hoffmann-La Roche)
Santen Pharmaceutical Company
SciFluor Life Sciences
Sumitomo Dainippon Pharma
U.S. FDA (Food and Drug Administration)
Valeant Pharmaceuticals International